S

SCI Pharmtech Inc
TWSE:4119

Watchlist Manager
SCI Pharmtech Inc
TWSE:4119
Watchlist
Price: 83 TWD -0.12% Market Closed
Market Cap: 9.9B TWD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SCI Pharmtech Inc stock under the Base Case scenario is 48.69 TWD. Compared to the current market price of 83 TWD, SCI Pharmtech Inc is Overvalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
48.69 TWD
Overvaluation 41%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

7
P/S
P/S
Price to Sales
7
vs History
52
vs Industry
16
Median 3Y
9.4
Median 5Y
8.6
Industry
2.4
Forward
6.4
More Details
20.5
P/E
P/E
Price to Earnings
20.5
vs History
57
vs Industry
11
Median 3Y
38.6
Median 5Y
28.9
Industry
20.5
Forward
18.8
More Details
103.2
P/OCF
P/OCF
Price to OCF
103.2
vs History
0
vs Industry
20
Median 3Y
36.7
Median 5Y
23.9
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-29.1
Median 5Y
-16.5
Industry
22.6
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
77
vs Industry
37
Median 3Y
2.3
Median 5Y
2.3
Industry
2
More Details
7.2
EV/S
EV/S
Enterprise Value to Sales
7.2
vs History
52
vs Industry
15
Median 3Y
9.6
Median 5Y
8.5
Industry
2.5
Forward
6.6
More Details
26.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
26.7
vs History
46
vs Industry
6
Median 3Y
33.3
Median 5Y
30.1
Industry
4.9
More Details
27.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.2
vs History
52
vs Industry
9
Median 3Y
37.7
Median 5Y
32.1
Industry
12.6
More Details
64.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
64.1
vs History
38
vs Industry
4
Median 3Y
76.3
Median 5Y
67
Industry
15.6
More Details
106.6
EV/OCF
EV/OCF
Enterprise Value to OCF
106.6
vs History
0
vs Industry
21
Median 3Y
38.2
Median 5Y
23
Industry
13.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-14
Median 5Y
-11.5
Industry
17.7
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
85
vs Industry
38
Median 3Y
2
Median 5Y
2
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
SCI Pharmtech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
SCI Pharmtech Inc
TWSE:4119
9.9B TWD 7 20.5 27.2 64.1
US
Eli Lilly and Co
NYSE:LLY
793.6B USD 17.6 74.9 43.5 48
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
393.8B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 8.1 23.3 15.3 17.4
CH
Roche Holding AG
SIX:ROG
246.5B CHF 4.2 21.4 11.9 14.2
US
Merck & Co Inc
NYSE:MRK
235.8B USD 3.7 13.8 9.3 10.9
UK
AstraZeneca PLC
LSE:AZN
180B GBP 4.3 33.1 127.1 194.1
CH
Novartis AG
SIX:NOVN
202B CHF 4.4 19.1 11.6 14.8
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.9B USD 2.3 18.5 8.8 12.5
P/E Multiple
Earnings Growth PEG
TW
S
SCI Pharmtech Inc
TWSE:4119
Average P/E: 28.1
20.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
74.9
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.4
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.8
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.1
36%
0.9
CH
Novartis AG
SIX:NOVN
19.1
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
S
SCI Pharmtech Inc
TWSE:4119
Average EV/EBITDA: 398.1
27.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.5
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
15%
1
CH
Roche Holding AG
SIX:ROG
11.9
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.3
9%
1
UK
AstraZeneca PLC
LSE:AZN
127.1
9%
14.1
CH
Novartis AG
SIX:NOVN
11.6
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
S
SCI Pharmtech Inc
TWSE:4119
Average EV/EBIT: 1 705.5
64.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
16%
1.1
CH
Roche Holding AG
SIX:ROG
14.2
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.8
8%
1.9
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.